ReviewFrontiers in oncology2017
Gliomatosis Cerebri: Current Understanding and Controversies.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Clinical and imaging features of lymphomatosis cerebri: analysis of 8 cases and systematic review of the literature.Clinical and experimental medicine · 2023Pooled it
- Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.Journal of neuro-oncology · 2018Pooled it
- Clinical Reasoning: A 66-Year-Old Female Patient With Rapidly Progressive Memory Changes.Neurology · 2025Article
- Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.Journal of neuro-oncology · 2025Article
- An atypical presentation of infiltrative diffuse low-grade glioma in an adolescent: case report.BMC neurology · 2025Article
- The role of chemotherapy in patients with gliomatosis cerebri: a population-based study.Neurosurgical review · 2025Article
- HMGN2 accelerates the proliferation and cell cycle progression of glioblastoma by regulating CDC20 expression.Genes & diseases · 2025Article
- Digital "flipbooks" for enhanced visual assessment of simple and complex brain tumors.Neuro-oncology · 2024Article
- Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.Journal of neuro-oncology · 2024Article
- Gliomatosis Cerebri Manifested as Parkinsonism Syndrome: A Case Report.Case reports in neurological medicine · 2024Article
- Article
- Gliomatosis cerebri with blindness: A case report with literature review.Radiology case reports · 2023Article
- An enduring debate on gliomatosis cerebri.Brain tumor pathology · 2023Review
- Clinical, Imaging and Neurogenetic Features of Patients with Gliomatosis Cerebri Referred to a Tertiary Neuro-Oncology Centre.Journal of personalized medicine · 2023Article
- Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report.Veterinary sciences · 2022Article
- Surgical treatment of diffuse and multi-lobes involved glioma with the assistance of a multimodal technique.Scientific reports · 2022Article
- A rare case of gliomatosis cerebri lurking beneath the shadows of a stroke mimic.Radiology case reports · 2021Article
- Article
- Aberrant Rac pathway signalling in glioblastoma.Small GTPases · 2021Review
- Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Gliomatosis cerebri (GC) is a rare, extensively infiltrating glioma involving multiple contiguous lobes of the brain. This lethal disease affects all age groups, and the majority of patients have a poor outcome despite aggressive treatment. Despite its initial recognition in 1938, GC remains a controversial entity with little consensus in its definition, histology, or treatment. The majority of GC tumors are astrocytic, although mixed phenotypes have been identified. Treatment of GC is challenging as surgery is generally not an option due to the extensive areas of brain involved, the benefit of radiation therapy is unclear, and no chemotherapy has proven efficacy. Due to the rarity of the disease and its heterogeneity, both at histopathological and molecular levels, it is difficult to conduct clinical trials tailored for this diagnosis. This review summarizes our current knowledge, examines clinical studies focusing on the treatment of GC, highlights ongoing challenges, and discusses the recent molecular insights into adult and pediatric GC. We conclude that, although no longer recognized as a distinct pathological entity, GC represents a unique disease phenotype. Given the histologic and molecular overlap with other diffuse gliomas, the research emphasis should be on investigating its unique invasive biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.